Moderna COVID-19 vaccine safe, efficacious in adolescents
Phase 2/3 data now published in The New England Journal of Medicine showed that the Moderna COVID-19 vaccine was safe and generated strong activity against SARS-CoV-2 in adolescents, with an immune response similar to that of young adults.
For the study, Kashif Ali, MD, a pediatrician at Kool Kids Pediatrics in Houston, and colleagues enrolled 3,732 participants aged 12 to 17 years and randomly assigned them to receive either the vaccine (n = 2,489) or placebo (n = 1,243).
The researchers recorded no serious adverse events related to the vaccine, and no cases of COVID-19 were reported 2 weeks after participants received the second dose, compared with four cases in the placebo arm.
In the primary analysis, the geometric mean titer ratio for neutralizing antibodies in adolescents relative to young adults was 1.08 (95% CI, 0.94-1.24), the authors said. Additionally, the absolute difference in serologic response was 0.2 percentage points (95% CI, –1.8 to 2.4), they noted
“The immune response was similar to that in young adults, and the vaccine was efficacious in preventing COVID-19,” the authors wrote.